Prevail Therapeutics
Clinical trials sponsored by Prevail Therapeutics, explained in plain language.
A gene therapy company developing treatments for neurodegenerative diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene therapy injection aims to halt fatal brain disease in babies Results expected Feb 2027 (estimated)
-
New gene therapy targets Parkinson's in patients with specific gene flaw
Disease control OngoingThis study tests a new gene therapy called LY3884961 in 32 people with moderate to severe Parkinson's disease who have a specific genetic change (GBA1 mutation). The treatment is given as a single injection into the fluid around the brain and spinal cord. The main goal is to chec…
Phase 1/2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Gene therapy injection aims to halt fatal brain disease in babies
Disease control OngoingThis early-phase trial is testing a single-dose gene therapy called LY3884961 in 7 infants with Type 2 Gaucher disease, a severe and rapidly fatal genetic disorder. The therapy is injected into the fluid around the brain and spinal cord to deliver a working copy of the faulty gen…
Phase 1/2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
One-Time gene shot could free gaucher patients from lifelong infusions
Disease control OngoingThis early-stage study tests a single intravenous dose of a gene therapy called LY3884961 in 15 adults with Gaucher disease type 1. The goal is to see if it is safe and can reduce or replace the need for ongoing enzyme replacement or substrate reduction therapy. Participants must…
Phase 1/2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Gene therapy trial targets inherited dementia
Disease control OngoingThis study tests a single-dose gene therapy called LY3884963 in 35 people with frontotemporal dementia caused by GRN gene mutations. The therapy aims to raise levels of a missing protein (progranulin) in the brain. Participants receive the treatment via injection into the fluid a…
Phase 1/2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC